Does Kava Show Up on a Drug Test? Kavalactones and Standard Panels

Kava is a plant preparation made from the root of Piper methysticum, a shrub native to the South Pacific. It is sold as a beverage in kava bars, as a powder or tea, and as a capsule or tincture marketed for relaxation and sleep support. Because it produces a mild calming effect and is widely available without a prescription, people who use kava regularly sometimes wonder whether it could trigger a nonnegative result on a workplace or clinical drug test. The short answer is that kava's active compounds, called kavalactones, are not targets of any standard drug test panel, and there is no credible published evidence that kava cross reacts with the immunoassay chemistries used in routine testing.

That answer deserves some unpacking, because "not on the panel" and "impossible to detect" are two different statements. This article explains what standard panels actually screen for, why kava falls outside that scope, what the regulatory record says about kava safety, and what a specialty laboratory can and cannot do if someone specifically wants kavalactones measured.

What a standard drug test panel actually screens for

Workplace and clinical drug testing programs almost always start with an immunoassay screen, run on a urine cup, a dip card, or an oral fluid device. An immunoassay uses antibodies built to recognize the general chemical shape of a target drug class. It does not scan a specimen for every possible substance a person might have consumed. It looks only for the specific analytes the assay was designed and validated against.

The most common configurations are the 5 panel, 10 panel, and 12 panel tests, which typically cover classes such as marijuana metabolites (THC), cocaine metabolites, opiates, phencyclidine (PCP), amphetamines and methamphetamine, benzodiazepines, barbiturates, and methadone, depending on how the panel is built. Federal workplace drug testing programs follow the Department of Health and Human Services Mandatory Guidelines, published at 42 CFR Part 85, the Mandatory Guidelines for Federal Workplace Drug Testing Programs, which set out the specific initial test analytes HHS certified laboratories must use. Transportation employers testing safety sensitive workers under Department of Transportation rules follow a parallel structure at 49 CFR Part 382, the DOT controlled substances testing regulation. Kava and kavalactones are not named analytes in either framework, because kava is not a federally controlled substance and was never built into standard panel design.

The Substance Abuse and Mental Health Services Administration, the agency that certifies the laboratories used in federal and most private sector testing, maintains program guidance at SAMHSA's workplace program page. Private sector dip cards, cups, and oral fluid devices generally model their panel design on this same federal structure, which is why kava does not appear as a target analyte on commercially available multi panel devices either.

Why kava is not part of the standard panel

Kavalactones are a family of lactone compounds, including kavain, methysticin, and yangonin, responsible for kava's calming and muscle relaxing effects. They are structurally distinct from the drug classes immunoassay panels are built to detect. Kavalactones are not opioids, not amphetamines, not benzodiazepines, and not cannabinoids, and they do not share the core chemical scaffolds that panel antibodies recognize. The chemical structure of kavain, one of the principal kavalactones, is documented in the National Institutes of Health's public chemistry database, PubChem's record for kavain, which shows a structure unrelated to any controlled substance class covered by standard panels.

Kava is also not scheduled under the federal Controlled Substances Act. The Drug Enforcement Administration publishes the current federal drug schedules, and kava and kavalactones do not appear on any schedule listed at the DEA Diversion Control Division's controlled substance schedules. Because a substance has to be either a named analyte on a specific panel or a close structural match to one of those analytes to trigger a cross reactive result, and kava meets neither condition, there is no published evidence of kavalactones causing a false positive on a marijuana, opiate, amphetamine, benzodiazepine, barbiturate, or any other standard panel. A negative result tells you the person was negative for the analytes on that specific panel, nothing more and nothing less about substances the panel was never designed to catch.

Immunoassay screening versus confirmation testing

It helps to separate the two steps used in almost every drug testing program. The first step is the immunoassay screen described above, a quick, low cost preliminary result. The second step, used only when the screen comes back nonnegative, is laboratory based confirmation testing using gas chromatography mass spectrometry (GC/MS) or liquid chromatography tandem mass spectrometry (LC/MS), which identifies the exact molecule by its mass and fragmentation pattern. The National Institute on Drug Abuse, part of the National Institutes of Health, describes this two step screen and confirm structure in its overview of drug testing science at NIDA's drug testing research topic page. Because kava is not an analyte on the initial immunoassay panel, it would not trigger a screen in the first place, and a medical review officer (MRO) would not expect kava use, by itself, to explain a positive result on a standard panel, because kava does not produce one.

Can a laboratory test specifically for kavalactones

A standard multi panel drug test, whether a rapid cup, dip card, or oral fluid device, will not detect kavalactones because no such target strip exists on those devices. Measuring kavalactones requires a dedicated laboratory method, typically liquid chromatography paired with mass spectrometry, run only when a client specifically requests kavalactone analysis for a research, clinical, or compliance purpose. This differs from how many people think about drug testing, where a single device is assumed to catch every possible substance. It does not. Any employer, clinic, or treatment program with a specific reason to measure kavalactones should ask a laboratory directly which analytes its reference testing actually covers.

What the safety record says about kava

Separate from drug testing, kava has its own safety profile worth understanding. The National Center for Complementary and Integrative Health, part of the National Institutes of Health, states plainly that various kava products have been linked to rare cases of liver injury, some of which have been serious. That consumer facing safety information is published at NCCIH's kava health information page, which also notes that contributing factors may include certain plant varieties, combining kava with alcohol, product contamination, individual susceptibility, and prolonged high dose use.

The Food and Drug Administration tracks kava in its Dietary Supplement Ingredient Directory, a reference list of ingredients the agency has taken action on or issued communications about. The directory places kava in the category reserved for ingredients subject to an FDA safety communication, tied to an earlier agency notice about kava containing products and the potential for severe liver injury. The current entry is available at the FDA's Dietary Supplement Ingredient Directory. Because kava is sold as a dietary supplement rather than an approved drug, it did not go through FDA premarket approval, and the directory listing reflects post market safety monitoring, not a product endorsement. This article is not medical advice about whether kava is safe for any individual; anyone with liver disease, anyone taking other medications, or anyone with general health questions about kava should talk to a physician or pharmacist.

How kava compares to other popular herbal and hemp products

Employers and clinics frequently ask the same question about other widely used herbal or hemp derived products. The table below summarizes how kava compares to kratom, CBD, and delta 8 THC on standard panel relevance. Actual panel coverage always depends on the specific device and laboratory a program uses.

Readers who want more on kratom's alkaloids and why rapid panels need a dedicated strip to catch them can review this related article on whether kratom shows up on a drug test. For how CBD products and THC panel cutoffs interact, see this companion article on whether CBD shows up on a drug test.

What employers and program administrators should do

Employers running a drug free workplace program generally do not need to add a kava specific test to their panel, since there is no published evidence that kava interferes with the controlled substance classes those panels detect. What employers should do is keep policies accurate: a negative result on a standard panel means the donor was negative for that panel's specific analytes, not that every substance was ruled out. If a program has a specific reason to screen for kavalactones, administrators should ask their laboratory which send out or reference methods are available, since that testing has to be requested separately.

Any case involving a nonnegative screen on a standard panel should still go through the normal review pathway: confirmation testing at an HHS certified or equivalently accredited laboratory, followed by medical review officer evaluation of prescription and over the counter product disclosures before any result is verified. Donors should disclose what they have taken, honestly and specifically, during an MRO interview, and kava use, if relevant to a specific case, should be disclosed the same way any other supplement would be. Employers and laboratories that need drug test cups, dip cards, or oral fluid collection devices for standard panel programs can review current options in the drug test cup collection at American Screening Corporation.

Evidence level, stated plainly

There is no published, peer reviewed evidence that kava or its kavalactones cross react with any standard immunoassay panel. This is a case of no credible cross reactivity evidence, not conflicting or disputed research. Kava is absent from the federal Mandatory Guidelines analyte list, absent from the DEA's controlled substance schedules, and chemically distinct from the drug classes those panels target. Separately, kava carries its own documented liver safety concern tracked by NIH and FDA, a different question from drug test detection that should be evaluated with a physician or pharmacist rather than guessed at from general information online.

Frequently asked questions

Does kava show up on a standard 5 panel or 10 panel drug test?

No. Kava's active compounds, kavalactones, are not analytes that standard immunoassay panels are built to detect, and there is no credible published evidence of cross reactivity with the drug classes those panels screen for.

What do standard drug test panels actually screen for?

Standard panels screen for specific controlled substance classes, such as marijuana metabolites, cocaine metabolites, opiates, PCP, amphetamines, benzodiazepines, and barbiturates, depending on the panel configuration. Federal programs follow the HHS Mandatory Guidelines analyte list, and panels do not scan broadly for every substance a person might have consumed.

Can a laboratory test specifically for kava or kavalactones?

Only through a dedicated method, typically liquid chromatography paired with mass spectrometry, ordered specifically for that purpose. No standard cup, dip card, or oral fluid device includes a kavalactone target strip, so routine panels will not report on kava even if it was used.

Is kava legal and controlled under federal law?

Kava and kavalactones are not listed on the federal controlled substance schedules maintained by the Drug Enforcement Administration. It is sold as a dietary supplement rather than an approved drug, which means it did not go through FDA premarket drug approval.

Does kava cause liver problems?

Health agencies have documented rare cases of serious liver injury associated with kava containing products, and the FDA tracks kava in its dietary supplement safety communications. This is a general health and safety question, not a drug testing question, and anyone with concerns should speak with a physician or pharmacist rather than rely on general information.

What should someone tell an MRO if kava use comes up in a testing case?

Disclose it honestly and specifically, the same way any other supplement or medication would be disclosed during a medical review officer interview. Kava is not expected to explain a nonnegative result on a standard panel, so its relevance to a specific case depends on the details the MRO is evaluating.

This article is general information about drug testing science and procedure, not medical or legal advice. Employers, clinicians, and donors should consult their medical review officer, laboratory, physician, or legal counsel for guidance specific to an individual case.